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A B S T R A C T
The proportion of the population over the age of 65 is growing the most rapidly due to the longevity revolution.
Frailty is prevalent in this age group and strongly associated with disability and hospitalization, having a sig-
niﬁcant impact on the costs of health and social care. New eﬀective interventions to delay or reverse frailty are
urgently required. Geroprotectors are a new class of drugs, which target fundamental mechanisms of ageing and
show promise in delaying the onset of or boosting resilience in frail older people. However, there are challenges
to their clinical translation. Here we review the literature for evidence that frailty can be delayed or reversed and
geroprotectors can improve frailty in murine models and in patients. We will then discuss the challenges, which
make their clinical testing complex and propose potential options for moving forward.
1. Introduction
Although currently there is no universally agreed operational deﬁ-
nition for frailty (Rodriguez-Manas et al., 2013), it is considered to be a
distinctive clinical syndrome related to the ageing process in which
multiple body systems gradually lose their in-built reserves, leading to
an accumulation of deﬁcits, and loss of resilience, i.e., the ability to
recover from adverse events (Whitson et al., 2016). It is often associated
with increased vulnerability and dependency. Around 10% of people
aged over 65 years have frailty, rising to 25–50% of those aged over 85
years (Clegg et al., 2013). With the population of those aged>65 years
due to nearly double in the next 30 years, there is an urgent need to ﬁnd
interventions to delay or reverse frailty and improve resilience in older
people so that they can maintain independence and good quality of life
for longer.
Recent progress in the ﬁeld of ageing research has led to the de-
velopment of interventions with the potential to target frailty, also
termed “geroprotectors” (Figueira et al., 2016). The main characteristic
of this new class of drugs is the ability to target fundamental mechan-
isms of ageing, such as responses to oxidative damage, inﬂammation,
senescence, which underpin multiple deﬁcits occurring simultaneously
(Bellantuono, 2018). For this reason, they are believed to have the
potential to delay or even reverse frailty in older people and improve
their responses to adverse events. Over 200 compounds have been
classiﬁed as geroprotectors, each reported to slow ageing and/or extend
lifespan in a variety of organisms (geroprotectors.org). Here we review
the literature for evidence that frailty can be reversed and that ger-
oprotectors can play an important role. We will then examine the
barriers, which prevent their clinical testing and propose potential
options to move forward.
2. Deﬁnition and assessment of frailty
Central to the assessment of whether frailty can be reversed is how
frailty is deﬁned and measured. There are two main deﬁnitions of
frailty. The “Fried frailty phenotypic model” deﬁnes frailty as a distinct
clinical syndrome meeting three or more of ﬁve phenotypic criteria:
weakness, slowness, low level of physical activity, self-reported ex-
haustion, and unintentional weight loss (Fried et al., 2001). It describes
patient characteristics, which, if present, can predict mortality risk. This
model also allows for the possibility of fewer characteristics being
present, in which case patients are considered pre-frail. By contrast, the
cumulative deﬁcit frailty model proposed by Rockwood assumes an
accumulation of deﬁcits (ranging from symptoms e.g., loss of hearing or
low mood, signs such as tremoring, through to various diseases such as
dementia) which can occur with ageing and, when combined, can be
captured in a ‘frailty index’ (FI). A higher FI is associated with increased
risk of death (Rockwood et al., 2005). Both Fried and Rockwood deﬁne
frailty quite diﬀerently with a high impact of physical impairments in
the Fried phenotype and accumulation of body deﬁcits in the Rockwood
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model, describing frailty as almost two separate conditions. Both have
limitations; the Fried frailty phenotype assessment is not very sensitive
as a quantitative measure while the Rockwood FI was designed as a tool
to measure severity of frailty after a comprehensive geriatric assess-
ment. It is not validated for measuring improvement in individuals after
an acute illness for example or an intervention. Even though the “Fried”
frailty phenotype and the “Rockwood” FI are most accepted as a mea-
sure of frailty (for review see (von Zglinicki et al., 2016), they are not
comprehensively used and often diﬀerent investigators establish their
own modiﬁed versions. In general, this makes a direct comparison of
studies to assess the eﬃcacy of interventions very diﬃcult.
3. Is it possible to delay or reverse frailty?
Increased physical activity – from household activities to structured
exercise training – has been proposed as a key intervention in treating
frailty (Aguirre and Villareal, 2015; Fried, 2016; Liu and Fielding,
2011). Although a large number of trials have provided evidence of
some beneﬁcial eﬀects of exercise interventions on populations with
frailty (systematically reviewed in (Cadore et al., 2013; Chin A Paw
et al., 2008; Daniels et al., 2008; Theou et al., 2011), it is very diﬃcult
to assess how meaningful these eﬀects are for patients in terms of im-
proving their ability to live independently or to overcome adverse
events. This is due to the diﬀerent deﬁnitions and measurements of
frailty used, the large heterogeneity of the applied exercise protocols
(i.e., type, frequency, duration), and the diﬀerences in age, gender, and
ethnicity of the participants. Even when randomized control trials
(RCT) were performed using a standardized operational deﬁnition of
frailty as inclusion criteria, the diﬀerences in measures of physical
performance resulted in variable outcomes (de Labra et al., 2015; Giné-
Garriga et al., 2014; Lozano-Montoya et al., 2017).
Only few studies have assessed frailty longitudinally at baseline and
post-intervention, but they appear to be more informative in addressing
whether exercise can not only treat, but also reverse frailty (Apóstolo
et al., 2018; Lee et al., 2012; Puts et al., 2017). Two separate studies,
which have used Fried Frailty Criteria (FFC) at baseline and as an
outcome measure, have shown signiﬁcant reductions in the prevalence
and level of frailty in community-dwelling elders after a multi-
component physical activity intervention of 6-months (Ng et al., 2015)
and 12-months duration (Cesari et al., 2015), respectively. While both
studies included pre-frail and frail participants as deﬁned by FFC, Ce-
sari et al. (Cesari et al., 2015) also included non-frail individuals. Cesari
et al. (Cesari et al., 2015) reported that both the prevalence of frailty at
12 months and the number of frailty criteria was signiﬁcantly reduced
following physical activity. Ng et al., 2015, reported that the physical
activity intervention lead to signiﬁcant reductions in the mean frailty
scores already at 3 months, which persisted to 6 months (end of in-
tervention) and was maintained at 12-month follow-up assessments
compared with the control group.
In other studies, exercise interventions have been combined with
nutritional consultation (Chan et al., 2012; Serra-Prat et al., 2017) and/
or supplementation (Kim et al., 2015). Chan et al., (Chan et al., 2012)
selected Taiwanese older adults that were considered pre-frail or frail
according to an adapted version of FFC and assessed frailty status di-
rectly after a 3-month intervention including exercise training (aerobic
and strength exercises, 3x/week) and nutritional consultation, and at a
6-month follow-up. At 3 months, the intervention group had a sig-
niﬁcantly higher improvement rate in frailty status (pre-frail to robust/
frail to pre-frail or robust) compared with the control group. However,
in contrast to the study by Ng et al. (Ng et al., 2015), this was not the
case at 6 or 12 months follow-up, suggesting that beneﬁcial eﬀects of
exercise might not last when intensive interventions are terminated.
Similarily, Serra-Prat et al. (Serra-Prat et al., 2017) studied the ef-
fect of an exercise intervention (aerobic, strength, and balance training)
combined with good nutrition on preventing frailty in community-
dwelling pre-frail older people. Along with baseline FFC assessments,
the participants were screened for malnutrition using the Short-Form
Mini Nutritional Assessment questionnaire (MNA-sf) and those at risk
were referred to the Nutritional Unit for further assessment, and the
establishment of the usual dietary recommendations. On follow-up at
12 months, fewer participants in the intervention group had evolved
from pre-frail to frail (4.9% vs. 15.3% respectively), and 15–20% of pre-
frail participants returned to robustness, although this eﬀect did not
reach statistical signiﬁcance.
The eﬀects of a combined exercise and nutritional supplementation
intervention have also been assessed (Kim et al., 2015). Frail (three or
more criteria according to FFC) community-dwelling Japanese women
were randomly divided into four groups: exercise (strength, balance,
and gait training) without (placebo) or with nutritional supplementa-
tion of milk fat globule membrane (MFGM), or MFGM/placebo only. At
post-intervention (3 months), the mean number of frailty criteria (out of
ﬁve) signiﬁcantly decreased in all four intervention groups. However,
the eﬀect was maintained at the 7-months follow-up only in the groups
receiving exercise. The number of participants with frailty decreased in
both exercise groups (exercise+ placebo, exercise+MFGM) compared
with control groups (placebo and MFGM only) with the combination of
exercise and MFGM showing the greatest eﬀect. Although not limited to
interventions of physical activity/exercise, a very recent systematic
review (Apóstolo et al., 2018) provides a comprehensive overview of
the eﬀects of diﬀerent types of interventions (e.g., physical activity,
multifactorial, psychosocial, cognitive, and nutritional) to prevent the
progression of pre-frailty and frailty in older adults. All of these studies
came to the conclusion that, amongst all interventions, exercise and
nutrition were the most successful in reducing frailty. In agreement
with Kim et al., (Kim et al., 2015), the combination of exercise and
nutrition was the most beneﬁcial for reducing frailty, while these im-
provements were not achieved when using either exercise or nutrition
alone.
Until now, only few studies have investigated the eﬀects of exercise
interventions on frailty as deﬁned by the Rockwood FI (Jones et al.,
2004). Within the Beijing Longitudinal Study of Ageing (BLSA), both
FFC and the Rockwood FI were assessed over a period of 8 years in
order to investigate the relationship between frailty and physical ac-
tivity (Ma et al., 2018). This study showed that low physical activity,
deﬁned by the self-reported questionnaire known as the “Beijing
Longitudinal Study of Ageing leisure time Physical Activity Ques-
tionnaire” (BLSA-PAQ), was associated with increased FFC (Fried et al.,
2001) and increased Rockwood FI (Jones et al., 2004), worse physical
function, and higher risk of mortality in Chinese older adults.
The relationship between self-reported physical activity and
Rockwood FI in older adults (above 50 years) has also been assessed
within the English Longitudinal Study of Ageing (ELSA) (Rogers et al.,
2017). More speciﬁcally, the Rockwood FI of participants classiﬁed as
non-frail at baseline (Rockwood FI below or equal to 0.25) was assessed
longitudinally over a period of 10 years in order to investigate how the
change in FI over time varies by intensity of weekly physical activity.
Compared to sedentary and mild physical activity (e.g., laundry, va-
cuuming), moderate physical activity (e.g., gardening, washing car)
reduced the progression of frailty only in some age groups (particularly
above 65 years) whereas vigorous activity (jogging, cycling at least 1x/
week) signiﬁcantly reduced the trajectory of frailty progression in all
older adults. The results of this study thus suggest that high intensities
of physical activity are needed in order to signiﬁcantly reduce trajec-
tories of frailty and should thus be encouraged, even at very old age. It
also highlights that exercise in combination with other interventions
can have additional eﬀects in delaying or reversing frailty.
All together, these data suggest that it is possible to delay or even
reverse frailty and that combination therapies may be better to max-
imize beneﬁts.
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4. Geroprotectors and frailty in preclinical studies
Both the FFC and the FI have been reverse translated into the
emerging ﬁeld of mouse frailty models (reviewed in (Kane et al., 2016b;
Seldeen et al., 2015), with both methodologies showing an increase in
frailty with age (Jones et al., 2004; Liu et al., 2014; Whitehead et al.,
2014). Based on the Rockwood deﬁcit accumulation model (Jones
et al., 2004), a mouse frailty index was established in which 31 para-
meters are assessed non-invasively (Whitehead et al., 2014). A mouse
frailty phenotype scale, mimicking the FFC, was also established (Liu
et al., 2014). Four criteria (grip-strength, walking speed, physical ac-
tivity, and endurance) were measured and for each criteria a scoring of
1.5 standard deviations below the group mean was considered positive.
When a mouse presented with at least three positive criteria, it was
categorized as frail. With this method, 9% of C57BL6/J mice were
classiﬁed as frail at 28 months of age, which is a similar incidence to
that observed in humans. As with studies in humans, researchers have
used modiﬁed versions. The so-called “Valenica Score” based on the
mouse equivalent of the FFC, is a measurement of ﬁve components
(weight loss, weakness (grip-strength), poor endurance and slowness
(incremental treadmill test) and low activity level (motor coordina-
tion)) (Gomez-Cabrera et al., 2017). Using this method, the frailty
status of male C57BL/6 J mice, with and without free access to a run-
ning wheel, was assessed at ages 17, 20, 23, 26, and 28 months. The
mice with free access to a running wheel performed signiﬁcantly better
than the sedentary animals in all the frailty criteria measured. At all
ages, the percentage of frail mice was signiﬁcantly higher in the se-
dentary mice compared to the wheel-runners. Graber et al. (Graber
et al., 2015) measured frailty using the Frailty Intervention Assessment
Value (FIAV) based on (Liu et al., 2014) and using the following four
criteria: inverted cling grip test (overall muscle strength and en-
durance), rotarod speed (overall neuromotor function, walking speed),
physical activity (mean km/week of voluntary wheel running), and a
derived endurance score (mean of maximum time on rotarod and grip
test). They measured FIAV before and after a 4-week intervention of
voluntary wheel running in individual adult (6 months) and old (28+
months) male C57BL/6 J mice (Graber et al., 2015). Voluntary wheel
running was able to maintain or improve the individual FIAV score in
both age groups, however, the adult mice beneﬁted more from the in-
tervention. It should be noted that only two of the old mice (n= 11)
were categorized as pre-frail and frail, respectively at baseline. Never-
theless, no mice were classiﬁed as frail after the exercise suggesting that
aerobic exercise may revert frailty both at earlier and later stages of life
in mice. This FIAV assessment tool was also used more recently to in-
vestigate the eﬀect of high intensity interval training (10-minute uphill
treadmill HIIT sessions 3x/week over 16 weeks) on frailty status in 24-
month-old male C57BL/6 J mice (Seldeen et al., 2018). In this study,
ﬁve of the six mice that were frail or pre-frail at baseline had reduced
FIAV scores after the intervention, with four ultimately becoming non-
frail/robust. Both studies showed improvements in multiple physical
performance indicators (strength, endurance and gait-speed), as well as
morphologic (e.g., ﬁber-type) composition (Graber et al., 2015), muscle
mass and ﬁber cross-sectional area (Seldeen et al., 2018) and metabolic
changes (e.g., mitochondrial biogenesis (Graber et al., 2015) and bio-
mass (Seldeen et al., 2018)) in response to the exercise intervention.
These data suggest that it is possible to measure frailty in mice and that
these measurements are suﬃciently discriminatory to measure im-
provement following interventions with similar outcomes to those seen
in patients.
Geroprotectors have shown an ability to delay the onset of multiple
tissues’ dysfunction, multiple concurrent age-related diseases and boost
resilience by modulating mechanisms of ageing such as senescence,
autophagy, and inﬂammation (Bellantuono, 2018; Riera and Dillin,
2015). Drugs such as rapamycin, resveratrol, metformin, senolytics
(e.g. ﬁsetin, dasatininb, and querectin), which remove senescent cells,
can improve the healthspan of multiple systems including cardiac,
cognitive, neuromuscular, metabolic, and immune systems, and slow
the development of cataracts, sarcopenia, osteoarthritis, osteoporosis,
atherosclerosis, and Alzheimer’s diseases in murine models (Baker
et al., 2016; Childs et al., 2016; Farr et al., 2017; Jeon et al., 2017;
Martin-Montalvo et al., 2013; Mitchell et al., 2018; Neﬀ et al., 2013;
Roos et al., 2016; Xu et al., 2018; Yousefzadeh et al., 2018). The evi-
dence that geroprotectors can delay the onset of multiple age-related
diseases suggest that they can improve aspects of frailty such as mul-
timorbidity, when present. The fact that they can improve deﬁcits in
multiple systems and increase reserves support the notion that they can
improve several clinically relevant measures associated with frailty,
including strength, endurance, balance, and walking speed (Martin-
Montalvo et al., 2013; Mitchell et al., 2018; Neﬀ et al., 2013; Xu et al.,
2015) and suggests that they have potential to delay or even reverse
frailty and to boost the ability to resist or recover from adverse events.
Indeed, the frailty index based on the Rockwood accumulation deﬁcit
model (FI) has been used in the testing of geroprotectors. Angiotensin II
inhibition by either receptor blockade or synthesis blockade has been
used as a primary and eﬀective medication in cardiovascular diseases
for decades. As levels of angiotensin II have been shown to increase
with ageing and many of its negative actions occur in age-related dis-
eases (Abadir, 2011; Dutka et al., 1996), these drugs have been re-
visited for various other indications including as a strategy to slow
ageing (Benigni et al., 2010; de Cavanagh et al., 2011; Kosugi et al.,
2006; Tuttle, 2006). Indeed, recently, the ACE inhibitor enalapril was
shown to attenuate frailty in older mice (Keller et al., 2018). Inter-
ventions using both calorie restriction and resveratrol, known to confer
improvement in healthspan across multiple organ systems (Bhullar and
Hubbard, 2015; Lee and Longo, 2016), were also associated with a
signiﬁcant reduction in FI scores in C57BL/6 J mice, compared with
age-matched controls (Kane et al., 2016a). Rapamycin, an inhibitor of
mTOR, and a well characterized geroprotector, reduced frailty and
improved long‐term memory, neuromuscular coordination, and tissue
architecture when administered to NFkb -/- mouse model of in-
ﬂammageing (Correia-Melo et al., 2019).
More studies are required to understand what aspects of frailty may
beneﬁt from the use of geroprotectors. Diﬀerences were noticed be-
tween using the FI as an outcome measurement and speciﬁc phenotypic
measurements, particularly those related to muscle performance. For
example, there was no correlation between FI and rotarod performance
when studying ageing in C57BL6/J mice (Kane et al., 2016a). In this
study, the two tests were 3 months apart, but these results support si-
milar ﬁndings in patient studies (Kulminski et al., 2008; Rockwood
et al., 2007). Geroprotectors may be more suitable for improving the
homeostasis or the reserve of multiple systems rather than focusing on
improving muscle performance per se. Therefore, they may be beneﬁcial
in improving the patients’ resistance or recovery to adverse events or
their response to tissue regenerative interventions. This has implica-
tions when choosing the most suitable measure of outcome. FI, which
covers a range of physiological systems including the integument and
musculoskeletal system, vestibulocochlear/auditory systems, ocular/
nasal systems, digestive system, urogenital system, and respiratory
system, and signs of discomfort, may be more appropriate. One note of
caution is that FI does not cover cognitive ability. Modiﬁcations to this
index to assess cognitive function are required. In addition, experiments
using FI require long-term studies and the changes in naturally ageing
mice are relatively small, which may limit the ability to detect small
improvements in a shorter time-frame. Beyond naturally ageing mice
there are a number of models of accelerated ageing which may develop
frailty more rapidly and with a more severe phenotype and thus may
oﬀer an opportunity to improve our mechanistic understanding of
frailty while speeding up testing. Models of inﬂammation, such as the
Interleukin (IL)-10 homozygous knock-out (KO) mouse, display signs of
frailty with muscle weakness and increased mortality which occurred
earlier than wild type mice (Ko et al., 2012; Walston et al., 2008).
However, the mice did not appear to show all aspects of the frail
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phenotype as there was no diﬀerence in weight, or activity level com-
pared with wild-type controls. This may be due to the fact that some of
the deﬁcits start when the animals are still developing and may require
deletion of the gene once they reach maturity to have a more com-
prehensive phenotype. Endurance and walking speed or any other
parameter included in the FI were not assessed. Another model of in-
ﬂammation, the NF-kB-/- mouse showed signs of frailty when measured
by FI but there was no detailed analysis of the individual components to
determine whether they accumulate speciﬁc defects (Correia-Melo
et al., 2019). A detailed characterization of transgenic mouse models of
premature ageing due to accumulation of DNA damage such as the
Werner syndrome mice or the Hutchinson–Gilford mice (for a review
see (Kõks et al., 2016), may also be informative. In addition, other
models such as telomerase knock-out (Terc-/- and Tert-/-), Atm knock-
out and polG mutator are deemed worthy of characterization. These
mouse models are known to interfere with important mechanisms of
ageing such as telomere shortening, oxidative damage, and mitochon-
drial dysfunction and to have multiple systems failure (Kõks et al.,
2016). It would also be of interest to assess frailty in response to
stressors such as administration of chemotherapy and radiotherapy,
immobilization, surgery, or procedures such as ovariectomy to test re-
silience (reviewed in (Kirkland et al., 2016; Schosserer et al., 2019).
Ovariectomy has been shown to produce an epigenetic pattern similar
to those seen with age (Stubbs et al., 2017). All of these models could be
useful in understanding the impact of frailty on resilience and the
ability of geroprotectors to improve reserve and response to adverse
events, in a way that would be more in line with clinical translation
(Schosserer et al., 2019).
5. Clinical translation
While eﬀorts to prevent frailty have mainly focused on lifestyle
interventions, the International Conference on Frailty and Sarcopenia
Research (ICFSR) Task Force has recognized that pharmacological ap-
proaches are likely required for individuals who meet frailty criteria or
who have comorbid conditions that contribute to and complicate the
frailty syndrome (Pahor et al., 2018). In this respect geroprotectors are
promising candidates for a pharmacological approach. Indeed, in recent
years geroprotectors have been used in a small number of exploratory
clinical trials (Table 1). Rapamycin is among the most studied ger-
oprotectors and, has been used in a safety clinical trial using non-im-
munosuppressive doses in patients with coronary artery disease un-
dergoing cardiac rehabilitation. Although there was no improvement in
measures of physical performance for frailty, there was an improvement
in IL6 levels, a marker associated with inﬂammation and senescence
(Singh et al., 2016) and reduced muscle function (Haddad et al., 2005).
The negative outcome may be explained by the small number of pa-
tients enrolled in the study, and by the fact that most patients were not
frail and they showed good quality of life at baseline as seen by robust
grip strength and high scores on SF-12 questionnaire. Indeed the study
by (Cesari et al., 2015) showed a larger eﬀect in the more frail patients
following intervention with exercise. A recently published pilot also
conﬁrmed similar results. Rapamycin was safely used in older volun-
teers (NCT02874924, (Kraig et al., 2018), but no signiﬁcant eﬀects
were observed in grip strength or walking speed used as measure of
frailty. This study also suﬀered from a small sample size and relatively
short treatment (8 weeks). In addition, the inclusion criteria were very
broad, enrolling participants in good health and clinically stable
chronic diseases. However, the doses used in both studies were in the
same range as those used in the study by (Mannick et al., 2014) where
administration of an analogue of rapamycin, was shown to improve
immune function in older people in response to inﬂuenza vaccine when
given alone (Mannick et al., 2014) or in combination with BEZ235
(Mannick et al., 2018). The combination therapy proved even more
eﬃcacious. The eﬀect of rapamycin on immune cells is thought to be
due to an anti-ageing mechanism. No assessment of any parameter of
frailty was performed in this study. However, aged immune cells are
thought to be, at least in part, responsible for the pro-inﬂammatory
phenotype which develops with age and that is associated with reduced
muscle mass and strength. The diﬀerences in eﬃcacy may be in the fact
that this was a much larger study and the measure of outcome was
focused on the immune system and not dependent on patient perfor-
mance on the day, which is likely to introduce much variability.
Testing with metformin has shown more positive results. Metformin
is used for the treatment of diabetes but is also one of the most widely
studied geroprotectors (Burkewitz et al., 2014; Piskovatska et al., 2018)
with eﬀects on lifespan (Anisimov et al., 2005; Bulterijs, 2011;
Menendez et al., 2011; Smith et al., 2010) and healthspan in animal
models and humans (Martin-Montalvo et al., 2013; Thomas and Gregg,
2017). Based on a meta-analysis, metformin was shown to reduce all-
cause mortality and diseases (Campbell et al., 2017). Clinical trial in
older adults with diabetes showed reduced risk of cognitive decline and
dementia (Ng et al., 2014) and reduced plasma cytokines in non-dia-
betic heart failure patients (TAYSIDE trial, (Cameron et al., 2016) in-
cluding the ageing-associated cytokine CCL11. As it is relatively safe
(Gregorio et al., 1996) and potentially oﬀ-patent, it is an attractive
candidate. Sumantri et al (2014) (Sumantri et al., 2014)showed a
protective eﬀect of metformin on the risk of frailty, assessed using a 40-
item FI, through improved grip strength and body balance. By contrast,
(Wang et al., 2014) identiﬁed a beneﬁcial eﬀect of metformin on
mortality, over other diabetes drugs administered in patients without
frailty but there was no beneﬁt to those patients already identiﬁed as
frail. As there is a very strong correlation between frailty and mortality,
this study suggests that there may be a critical window for intervention
with metformin for the improvement of frailty. Both studies analysed a
higher number of patients compared to the studies with rapamycin.
When looking at combination therapy, one clinical study combined
metformin with physical activity. Contrary to expectation, the study
showed that metformin inhibited the improvement in skeletal muscle,
mitochondrial respiration, and attenuated the increase in protein
synthesis and whole‐body insulin sensitivity after aerobic exercise
training (Konopka et al., 2019). It suggests that additional studies are
needed to understand the mechanisms that elicit positive and negative
responses to metformin. Indeed, further clinical studies are underway
assessing the eﬀect of metformin directly on frailty alone or in combi-
nation with exercise (table1).
Much hope is pinned for the use of senotherapeutics, i.e. senolytics,
which eliminate senescent cells and senostathics which neutralise the
senescence-associated secretory phenotype (SASP) (Kirkland and
Tchkonia, 2015; Kirkland et al., 2017; Tchkonia and Kirkland, 2018).
Accumulation of senescent cells was shown to be a major contributor to
frailty and age-related diseases in general (Tchkonia et al., 2013). The
majority of senotherapeutics are repurposed drugs with well-known
safety proﬁles. Their safety proﬁle may also represent the most im-
portant limiting factor for systemic application as they interact with
CYP450 enzymes which metabolise 90% of drugs and it can interfere
with the metabolism and kinetic of other drugs in patients with complex
medical needs and polypharmacy (Zhu et al., 2017). However, they can
be used at intermittent dosing limiting the side eﬀects. Studies with
quercetin in combination with dasatinib and ﬁsetin are ongoing
(Yousefzadeh et al., 2018) in a variety of conditions and healthy older
volunteers (Table 1). Of interest is the very recently published study
using quercetin and dasatinib in Idiopathic Pulmonary Fibrosis where
there was a signiﬁcant improvement in 6-min walk test, 4-m gait speed,
and chair-stand time (Justice et al., 2019). Eight of 14 participant's FI-
LAB scores, (frailty index based on commonly used laboratory tests)
(Rockwood et al., 2015) improved by at least 5%, but the mean dif-
ference did not reach signiﬁcance and similarly trend to improvement
of the SASP phenotype were seen but the sample size was too small to
reach any meaningful conclusion. The major limitation of this study is
the absence of a control group and therefore the functional improve-
ments observed must be interpreted with caution. An appropriately
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powered randomized controlled trial is required.
Studies with ﬁsetin and rosveretrol are ongoing and we will have to
wait the outcome of those studies. However, the present completed
trials have already highlighted the challenges in designing appropriate
and cost-eﬀective clinical trials. Firstly, the recruitment of a suﬃcient
number of patients, and secondly the standardization of inclusion and
exclusion criteria and measures of outcomes. Many of these patients
have complex medical needs and are usually not included in clinical
trials for this reason.
6. Challenges in clinical translation and way forward
The major challenge facing clinical trials for frailty is that there is no
appropriate regulatory framework for the use of drugs targeting frailty.
Frailty is not considered an indication the US Food and Drug
Administration (FDA) or European Medicines Agency (EMA) and
therefore drugs for frailty are not eligible for reimbursement by the
health systems and regulatory bodies are reluctant to give approval to
perform clinical trials for frailty. This does not give an incentive to the
pharmaceutical companies to invest in the development of such drugs.
It limits the resources available, the size of the trials, and the trial de-
sign. This in turn results in small trials with a mix of outcomes. For
frailty to become an indication, there are a number of factors to ad-
dress. The indication has to be well deﬁned; animal models of the
condition that reﬂect the majority of the aspects of the indication
should be available; and there is also a need for clearly deﬁned selec-
tion criteria and measurable outcomes, which show a beneﬁt to the
patient and ideally can be closely reproduced in the preclinical setting.
Although there is a general agreement on the necessity and use-
fulness of frailty as a clinical entity, there is still a lack of both a con-
sensus deﬁnition and standardized assessments for use in clinical
practice and research. The most common deﬁnition of frailty is a
medical state with multiple causes and contributors that is character-
ized by diminished strength and endurance and reduced physiologic
function that increase an individual’s vulnerability to stressors. These
can range from minor stressors, such as an infection or a new medica-
tion, to more serious events, such as surgical interventions, leading to
potentially serious consequences, increased dependency and/or death.
Frailty can be associated to multimorbidity but can also exist in absence
of multimorbidity, complicating the deﬁnition even further (Marengoni
et al., 2018; Palmer et al., 2018; Vetrano et al., 2018a, b; Zucchelli
et al., 2018). There are eﬀorts made in this direction, but a consensus
deﬁnition is proving diﬃcult to achieve. This may be due to the fact
that under the same denomination there may be more than one con-
dition and more knowledge on the biology of frailty and the molecular
mechanisms driving is required to inform consensus.
In the meantime, there may be opportunities to develop more
knowledge on frailty and how to treat it by studying the detrimental
association of frailty with other pathologies. For example, in cancer the
chemotherapy and radiotherapy treatments are signiﬁcant stressors
that have the potential to challenge physiological reserve. A systematic
review has identiﬁed that prevalence of frailty, and pre-frailty in older
cancer patients is high, with the median estimates of 42% and 43%,
respectively (Handforth et al., 2015). Older people with frailty and pre-
frailty (in which one or two criteria of the Fried Frailty phenotype are
present and are at high risk of progressing to frailty) are at considerably
increased risk of all-cause mortality, postoperative mortality, che-
motherapy intolerance, and postoperative complications (Handforth
et al., 2015). They could potentially beneﬁt from pre-treatment with
geroprotectors to decrease their vulnerability to a stressor and boost
resilience. Similarly, patients with COPD show an increase in frailty
associated with higher mortality (Maddocks et al., 2016). Frailty is one
of the main causes of reduced compliance with pulmonary rehabilita-
tion and therefore an improvement in frailty would be advantageous
(Maddocks et al., 2016). Frailty is also common in older patients with
hip fracture, where it is associated with increased time in hospital and
postoperative complications. Time in hospital doubled between patients
with an intermediate frailty index and a high frailty index, suggesting
that improving frailty could have signiﬁcant eﬀects on the time spent in
hospital and on the ability to recover (Krishnan et al., 2014). Ger-
oprotectors are unlikely to be curative on their own but could be tested
in combination with existing treatments for the underlying condition to
provide a healthier status for patients. This could then boost responses
and improve the outcomes of existing interventions for individual
conditions, which would provide the indication for reimbursement.
Improved responses with the same agent across multiple conditions
associated with frailty as common denominator would support the
concept that what had been targeted was the underlining condition of
frailty.
The identiﬁcation of standardized criteria for the selection of pa-
tients and the identiﬁcation of endpoints to test the eﬃcacy of ger-
oprotectors to boost resilience in frail individuals is urgently required.
In selecting a target population at risk of frailty, many factors need to be
considered, including age, low physical activity, impaired physical
function, impaired cognition, disability comorbidities, involuntary
weight loss, incontinence, polypharmacy, and sensory deﬁcits. In the
LIFE study, the physical activity intervention was most eﬀective in the
most frail group (Cesari et al., 2015). However, the recent study com-
bining metformin and exercise (Konopka et al., 2019) suggest that there
may be a window when an intervention is most eﬀective. Therefore,
stratiﬁcation of patients with diﬀerent degree of frailty needs to be
considered to understand who is beneﬁting the most.
Looking at the ongoing trials and considering the biology of these
drugs which are designed to improve cellular and tissues’ ﬁtness and
improve tissue reserves, this could be achieved by a combination of
geriatric assessment, the Rockwood FI (Rockwood et al., 2005), and
mobility tests such as those included in the Short Physical Performance
Battery Tests. They could be used as both selection criteria and as a
measure of outcomes. Measures of mobility are more acceptable to the
regulatory authorities because mobility is widely recognized as an im-
portant prognostic factor in geriatric care. Mobility has been well
documented as to its relation to multiple adverse outcomes in older
persons, and has been studied as to how it relates to clinically mean-
ingful change. The measures are taken with instruments that have
reasonable validity, reliability, and sensitivity to change. However,
mobility alone is not suﬃcient, as the advantage of geroprotectors is in
in their multi-system approach, beneﬁting frailty – both in association
with multiple chronic conditions or alone. The Rockwood FI is more
likely to capture this aspect. Patient-related outcome measures (PROs)
should also be considered as they better measure the impact of the
intervention on the quality of life. However, such PROs need to be
harmonized so that a direct comparison of results is possible. More
exploratory measures of outcome are being investigated which include
digital assessment by mobility devices, smart insoles and carpets, as
well as smart phone applications. A big advantage of such technologies
is that it is a continuous assessment in the home and/or normal en-
vironment and, thus, much more representative for the daily activity
than any traditional assessment in the clinical environment. However,
dealing with frail patients makes use of such digital devices challenging
and patient compliance needs to be addressed together with caregivers.
The search for “frailty” biomarkers is ongoing and no “unique” marker
has yet been identiﬁed, which detects frailty across cohorts and popu-
lations. It has been recently proposed to build biomarker panels or in-
dices for frailty similar to the Rockwood FI based on markers related to
pathways involved in frailty and ageing (see (Cardoso et al., 2018)).
Ideally, patients should be monitored using biomarkers, as they are less
likely to be inﬂuenced by the patient state on the day of the test and
also would allow closer monitoring over time.
7. Conclusions
Geroprotectors hold great promise for the treatment of frailty. New
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treatments are urgently required as frailty impacts on the ability to
maintain independent living and on quality of life of older people. This
also has implications for health and social care spending, which are
feared to become unsustainable in high-income countries at the pro-
jected rate of growth of those aged over 65. So far testing has been
limited, mainly focused on safety as primary endpoint and with patchy
results due to the small sample size and the great variability in study
design. This makes direct comparison of the studies for eﬃcacy diﬃ-
cult. Multi-centre, large international studies harmonized for inclusion
criteria and outcome measures are required to better understand the
potential and limitations of geroprotectors for frailty. They should be
supported by large governmental investments and produce evidence of
their eﬃcacy. It is possible that more sensitive measure of frailty, based
on the speciﬁc impaired mechanisms driving frailty, are required to
better stratify patients. This may use a combination of functional and
molecular biomarkers and may involve a much deeper understanding of
the molecular pathways underpinning frailty. It is likely that under a
common denomination there are diﬀerent molecular determinants and
syndromes. Such knowledge may lead to a new classiﬁcation of frailty
syndromes and may help ﬁnding consensus on how to deﬁne frailty.
Demonstration of eﬃcacy, combined with an agreed deﬁnition re-
cognized by entities such as WHO, EMA and FDA will show a clear
route to market. This is required to de-risk investments and enable the
pharmaceutical industry to embrace this approach. This in turn will
speed up progress.
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